608 related articles for article (PubMed ID: 8973696)
1. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
[TBL] [Abstract][Full Text] [Related]
2. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of prostAsure index in the detection of prostate cancer: a preliminary report.
Babaian RJ; Fritsche HA; Zhang Z; Zhang KH; Madyastha KR; Barnhill SD
Urology; 1998 Jan; 51(1):132-6. PubMed ID: 9457308
[TBL] [Abstract][Full Text] [Related]
4. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.
Björk T; Piironen T; Pettersson K; Lövgren T; Stenman UH; Oesterling JE; Abrahamsson PA; Lilja H
Urology; 1996 Dec; 48(6):882-8. PubMed ID: 8973671
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic significance of prostate-specific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems.
Manseck A; Pilarsky C; Froschermaier S; Menschikowski M; Wirth MP
Urol Int; 1998; 60(1):25-7. PubMed ID: 9519417
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
[TBL] [Abstract][Full Text] [Related]
7. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
[TBL] [Abstract][Full Text] [Related]
8. Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
de la Taille A; Houlgatte A; Houdelette P; Goluboff ET; Berlizot P; Ricordel I
Br J Urol; 1998 Sep; 82(3):389-92. PubMed ID: 9772876
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
[TBL] [Abstract][Full Text] [Related]
10. Total and free PSA: a methodical and clinical evaluation of five assays.
Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
[TBL] [Abstract][Full Text] [Related]
11. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
[TBL] [Abstract][Full Text] [Related]
12. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
[TBL] [Abstract][Full Text] [Related]
13. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA.
Van Cangh PJ; De Nayer P; De Vischer L; Sauvage P; Tombal B; Lorge F; Wese FX; Opsomer R
Urology; 1996 Dec; 48(6A Suppl):67-70. PubMed ID: 8973703
[TBL] [Abstract][Full Text] [Related]
14. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
Okihara K; Cheli CD; Partin AW; Fritche HA; Chan DW; Sokoll LJ; Brawer MK; Schwartz MK; Vessella RL; Loughlin KR; Johnston DA; Babaian RJ
J Urol; 2002 May; 167(5):2017-23; discussion 2023-4. PubMed ID: 11956430
[TBL] [Abstract][Full Text] [Related]
16. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.
Egawa S; Soh S; Ohori M; Uchida T; Gohji K; Fujii A; Kuwao S; Koshiba K
Cancer; 1997 Jan; 79(1):90-8. PubMed ID: 8988731
[TBL] [Abstract][Full Text] [Related]
17. Serum free prostate-specific antigen in the diagnosis of prostate cancer.
Leung HY; Lai LC; Day J; Thomson J; Neal DE; Hamdy FC
Br J Urol; 1997 Aug; 80(2):256-9. PubMed ID: 9284198
[TBL] [Abstract][Full Text] [Related]
18. Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Goepel M; Tscholl R
Br J Urol; 1998 Apr; 81(4):532-8. PubMed ID: 9598623
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of patients with diseases of the prostate using prostate-specific antigen density.
Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G
Br J Urol; 1995 Jul; 76(1):41-6. PubMed ID: 7544203
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
